Acinetobacter baumannii ADC-25 OXA-23 OXA-66 (CDC & FDA AR Isolate Bank #0282), Lung Infection Model, CFU Data

  1. image
CONTACT CUSTOMER SERVICE
  ADD TO FAVORITES
  ADD TO PANEL
OVERVIEW
DOCUMENTS/REFERENCES
RELATED SERVICES
RELATED PRODUCTS
BIOLOGICAL INFORMATION
BACKGROUND INFORMATION
This assay assesses the antimicrobial efficacy of test articles in a thigh muscle infection model with a carbapenem resistant Acinetobacter baumannii strain.  The microbial counts in tissue are measured.  This carbapenem resistant A. baumannii strain produces TEM-1D, ADC-25, OXA-23, and OXA-66 beta-lactamases. It is resistant to beta-lactam antibiotics, aminoglycosides and quinolones. It is susceptible to colistin and tigecycline. The FDA CDC Antimicrobial Resistance Isolate Bank supplied this strain.
SPECIES
Acinetobacter baumannii
STRAIN COMMON NAME
(#0282)
ORGANISM
Gram-negative Bacteria
INCUBATION CONDITIONS
Aerobic
ANTIBIOTIC RESISTANCE GENES
ADC-25,aph(3')-Ic,armA,mph(E),msr(E),OXA-23,OXA-66,strA,strB,sul2,TEM-1D
SOURCE
STRAIN SOURCE
CDC & FDA AR Isolate Bank
STRAIN SOURCE ID
AR Bank #0282
ASSAY INFORMATION
ASSAY TYPE
In Vivo
TESTING INFORMATION
PROCEDURE SUMMARY
Groups of 5 neutropenic mice are used. Animals are inoculated with pathogen suspension then test articles or vehicle are administered at time points after inoculation.  Doses may be administered IV, SC, PO, IM, IP or by IV infusion. At 24 after the first treatment, animals are humanely euthanized and tissue is aseptically removed.  Tissue is homogenized and pathogen counts are determined by plating to agar medium.  Pathogen counts from treatment groups are compared to vehicle groups and the signficance of an effect is determined.
TURNAROUND TIME
STANDARD
25 Days
CLINICAL RELEVANCE
THERAPEUTIC AREA
Infectious Disease
ADDITIONAL INFORMATION
BRAND
PDS
TESTING LOCATION
Taiwan - Taipei
OTHER INFORMATION
We will readily accommodate client-specified alterations. These studies are performed at our AAALAC accredited BSL-2 laboratory in Taipei, Taiwan. All aspects of this work are performed in general accordance with the Guide for the Care and Use of laboratory animals (National Academy Press, Washington, DC, 2011). The study protocol was approved by the Pharmacology Discovery Services IACUC and is performed with the oversight of veterinarians to assure the humane treatment of laboratory animals.

 

© Copyright 2026, Pharmacology Discovery Services – Privacy Policy | Cookie Notice | Cookie Preferences